<DOC>
	<DOCNO>NCT00163072</DOCNO>
	<brief_summary>Rationale : Megestrol acetate ( MegaceÂ® ) progestin analog FDA approve palliative treatment breast endometrial carcinoma . It also commonly use appetite stimulant , particularly HIV cancer patient poor appetite primary disease and/or therapy . Megace well absorbed orally , however , many patient , particularly young one difficulty take oral medication . Transdermal progestins available FDA approve . For example , Ortho EvraTM transdermal contraceptive patch contain estrogen ( ethinyl estradiol ) progestin ( norelgestromin ) . Key Objectives : Compare pharmacokinetics orally administer vs. transdermal Megace determine local side effect transdermal route .</brief_summary>
	<brief_title>Pharmacokinetics Safety Transdermal Megestrol Acetate</brief_title>
	<detailed_description>Study Population : Patients age already receive oral Megace appetite stimulant . Patients must indwell IV catheter order draw drug level . Major Inclusion &amp; Exclusion Criteria : Known hypersensitivity transdermal vehicle . Taking medicine would interfere Megace assay . Weight le 10 kg . Allocation Groups : Patients serve control . Summary Procedures : Patients stable dose oral Megace . To determine steady state peak level half-life patient , blood ( 2cc ) drawn level clinic 3 hour oral dose , daily 1-3 day . Patients may resume oral Megace , must stop medicine least 5 half-lives prior transdermal dose . The transdermal dose apply gel transparent patch clinic , blood collect prior , 10 , 30 , 60 , 90 , 120 minute , 4 hour dose . The patch remove 4 hour blood level . The patient return follow day 24 hour level , patient examine briefly local effect drug vehicle , may resume oral dose . Major Risks &amp; Discomforts : Patients need clinic 3-5 separate day , one last least 4 hour , drug level draw . There may mild skin reaction transdermal vehicle Megace .</detailed_description>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>Patients age already receive oral Megace appetite stimulant . Patients must indwell IV catheter order draw drug level . Known hypersensitivity transdermal vehicle . Taking medicine would interfere Megace assay . Weight le 10 kg .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>transdermal</keyword>
	<keyword>Megace</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>